Eli Lilly And Company - Company Profile
Access all 5,000+ company profiles through the Benchmarking Pro Membership. Unlock interactive competitor comparison tools that show you how Eli Lilly And Company stacks up to the competition and put relevant competitor and industry information at your fingertips.
Eli Lilly And Company - Overview
Brands
Alimta, Byetta, Cialis, Cymbalta, Darvocet, E-Mycin, Effient, Evista, Forteo, Gemzar, Glucagon, Humatrope, Humulin, Methadone, Prozac, ReoPro, Secobarbital, Strattera, Xigris, Zyprexa
Description
Eli Lilly And Company is a public company headquartered in Indiana with an estimated 45,150 employees. In the US, the company has a notable market share in at least two industries: Brand Name Pharmaceutical Manufacturing, Insulin Manufacturing and Brand Name Pharmaceutical Manufacturing. Their largest market share is in the Insulin Manufacturing industry, where they account for an estimated 40.1% of total industry revenue.
Company Details
- Registered Name: Eli Lilly And Company
- Company Type: Operating
- Exchange: NYSE
- Headquarters: 893 Delaware St, Indianapolis, IN 46225
- Website: http://www.lilly.com/
- Employees: 45,150
Eli Lilly And Company - Operating Industries and Main Competitors
-
OD5310 - Insulin Manufacturing
-
- Eli Lilly And Company Market Share: x.x%
- Sanofi Market Share: x.x%
- Novo Nordisk A Market Share: x.x%
-
32541a - Brand Name Pharmaceutical Manufacturing
-
- Eli Lilly And Company Market Share: x.x%
- Ucb S.A. Market Share: x.x%
- Abbvie inc. Market Share: x.x%
- Pfizer Inc. Market Share: x.x%
- Bristol-Myers Squibb Sa Market Share: x.x%
Eli Lilly And Company - Products and Services
Insulin Manufacturing
Of the 2 core revenue-generating products and services in the Insulin Manufacturing industry, Eli Lilly And Company offers:
- Long-acting insulin
- Premix insulin
Brand Name Pharmaceutical Manufacturing
Of the 8 core revenue-generating products and services in the Brand Name Pharmaceutical Manufacturing industry, Eli Lilly And Company offers:
- Cardiovascular prescriptions
- Diabetes prescriptions
- Mental health and nervous system prescriptions
- Oncology prescriptions
- Other prescriptions
Eli Lilly And Company - SWOT Analysis
Strengths and weaknesses take into account internal factors, and are based on Eli Lilly And Company's performance in comparison to its competitors. Opportunities and Threats focus on external influences, and are based on trends and demand in the Insulin Manufacturing , Brand Name Pharmaceutical Manufacturing industries
Strengths
Days Receivables: x.x%
Rank: 2 of 3 peers
Annual Turnover: x.x%
Rank: 2 of 3 peers
Weaknesses
Credit Risk: x.x%
Rank: 2 of 3 peers
Revenue per Employee: $xx
Rank: 2 of 3 peers
Opportunities
Threats
- AAAAA
- AAAAA
- AAAAA
Looking for IBISWorld Industry Reports?
Gain strategic insight and analysis on 700+ in the United States industries
(& thousands of global industries)
Eli Lilly And Company - Financial Statements
Eli Lilly And Company Income Statement
| BALANCE DATE | 12/31/2018 | 12/31/2019 | 12/31/2020 | 12/31/2021 | 12/31/2022 | 12/31/2023 |
|---|---|---|---|---|---|---|
| Revenue | 21,493.3 | 22,319.5 | 24,539.8 | 28,318.4 | 28,541.4 | 34,124.1 |
| Cost of Revenue | ||||||
| Cost of Revenue, Non-Cash | ||||||
| Gross Profit | ||||||
| 00000 |
Eli Lilly And Company Balance Sheet
| BALANCE DATE | 12/31/2018 | 12/31/2019 | 12/31/2020 | 12/31/2021 | 12/31/2022 | 12/31/2023 |
|---|---|---|---|---|---|---|
| Cash and Equivalents | 7,320.7 | 2,337.5 | 3,657.1 | 3,818.5 | 2,067.0 | 2,818.6 |
| Short-Term Investments | ||||||
| Derivative Assets, Current | ||||||
| Restricted Cash and Investments | ||||||
| 00000 |
Eli Lilly And Company Cash Flow
| BALANCE DATE | 12/31/2018 | 12/31/2019 | 12/31/2020 | 12/31/2021 | 12/31/2022 | 12/31/2023 |
|---|---|---|---|---|---|---|
| Net Income | N/A | N/A | N/A | N/A | N/A | N/A |
| Income (Loss) From Discontinued Operations | ||||||
| Depreciation, Depletion and Amortization | ||||||
| Amortization of Financing Costs and Discounts | ||||||
| 00000 |
Why purchase access to Benchmarking Pro?
This profile on Eli Lilly And Company includes:
- Company Overview
- Company Revenue and Employee Data
- Company Financial Statements
- Industry Market Share Breakdown
- Industry Competitor Matrix
- SWOT Analysis
- Products and Services
- Key Company Benchmarks
- Interconnected Competitor Profiles and Industry Reports
- Full Access to Benchmarking Pro
The IBISWorld Benchmarking Pro solution enables you to:
- Understand an enterprise’s competitive landscape and how they perform within a like-sized industry segment.
- Benchmark companies against industry averages, segment averages and their competitors.
- Identify real-world strengths, opportunities, weaknesses and threats for companies.
- Target growth opportunities or spot red flags in a business growth strategy.
- Toggle between company profiles and industry reports for a 360 degree view of a company's position.
IBISWorld provides profiles on thousands of leading companies around the world. Our clients rely on our information and data to stay up-to-date on business and industry trends across all sectors of the economy. This company profile, along with the corresponding competitor and industry data provided, includes thoroughly researched, reliable and current information that will help you to make faster, better business decisions.
Get Instant Access with Benchmarking Pro Membership
Benchmarking Pro
What's Inside
Benchmarking Pro?
A suite of company and industry data that:
- Benchmarks companies against industry averages or like-sized segments, as well as close competitors
- Identifies real-world strengths, opportunites, weaknesses and threats
- Reveals growth opportunities or red flags in a business growth strategy
Included in Report
-
Enterprise History & Synopsis
-
Company Financial Statements
-
Industry Market Share Breakdown
-
Industry Competitor Matrix
-
SWOT Analysis
-
Products and Services
-
Key Company Benchmarks
